Exhibit 99(h)

SCHERING-PLOUGH REPORTS SALES, EARNINGS
FOR 2001 SECOND QUARTER, FIRST HALF

2001 Second Quarter Diluted Earnings Per Share 43 Cents

KENILWORTH, N.J., July 25, 2001 -Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2001 second quarter and first half. Diluted earnings per share for the 2001 second quarter were 43 cents (as estimated in a June 28, 2001, press release) on net income of $634 million, which is flat compared with 43 cents on net income of $634 million in the 2000 second quarter. Second quarter 2001 sales of $2.6 billion were also flat compared with last year. Excluding exchange, second quarter sales increased 3 percent.

Diluted earnings per share for the 2001 first half decreased 5 percent to 81 cents on net income of $1.2 billion versus 85 cents on net income of $1.3 billion in 2000. First half 2001 sales of $4.9 billion were 1 percent lower than the $5.0 billion recorded in 2000. Excluding exchange, 2001 first half sales increased 1 percent.

"Worldwide pharmaceutical sales for the second quarter included strong demand for a number of the company's newer products," said Richard Jay Kogan, chairman and chief executive officer. "We also continue to see good growth in our international markets, driven by higher sales in the allergy/respiratory and anti-infective/anticancer product categories." Commenting on previously reported manufacturing issues, he said, "We have made progress toward resolving these manufacturing issues and I remain committed to getting Schering-Plough back on a solid growth track."

2001 SECOND QUARTER RESULTS

In the 2001 second quarter, worldwide pharmaceutical sales totaled $2.2 billion, with growth flat compared with the 2000 period (up 2 percent when foreign exchange is excluded). Higher sales for the 2001 second quarter were recorded in the allergy/respiratory and dermatologicals categories. Worldwide sales of the CLARITIN (loratadine) nonsedating antihistamine line, the world's No. 1 antihistamine, grew 3 percent to $925 million. Second quarter 2001 worldwide sales of NASONEX (mometasone furoate monohydrate) Nasal Spray, a once-daily nasal spray for allergies, increased 51 percent to $183 million. Sales of the anti-infective/anticancer INTRON A franchise totaled $315 million, down 13 percent versus the comparable year-ago period. The franchise includes INTRON A (interferon alfa-2b); PEG-INTRON (peginterferon alfa-2b), a longer-acting form of INTRON A (as monotherapy for treating hepatitis C and, internationally, in combination with REBETOL (ribavirin, USP) Capsules); and REBETRON Combination Therapy containing INTRON A and REBETOL.

Second quarter worldwide sales of TEMODAR (temozolomide), for treating certain types of brain tumors, were $44 million, up 46 percent. Sales of INTEGRILIN (eptifibatide) Injection, a glycoprotein platelet aggregation inhibitor for the treatment of patients with acute coronary syndromes, totaled $67 million, up 60 percent, and sales of REMICADE (infliximab), for the treatment of rheumatoid arthritis and Crohn's disease, were $36 million.

U.S. pharmaceutical sales in the 2001 second quarter totaled $1.4 billion, down 4 percent versus the 2000 period, with sales affected by manufacturing issues and changes in the timing of trade buying, tempered by increased demand for certain products. In allergy/respiratory, second quarter 2001 U.S. sales of the CLARITIN line were $782 million, up 2 percent. Domestic sales of NASONEX increased 56 percent to $145 million in the 2001 second quarter. In anti-infective/anticancer, U.S. sales of the INTRON A franchise totaled $147 million, down 32 percent. Second quarter domestic sales of TEMODAR rose to $26 million, up 55 percent. Sales of cardiovascular products in the 2001 second quarter were down 24 percent due to continued generic competition for IMDUR (isosorbide mononitrate), a once-daily, long-acting oral nitrate for angina, and lower sales of K-DUR® (potassium chloride USP), a sustained-release potassium supplement. Domestic sales of INTEGRILIN increased 58 percent to $61 million.

International pharmaceutical sales in the 2001 second quarter increased 6 percent (up 13 percent when foreign exchange is excluded) to $833 million. In allergy/respiratory, combined international sales of CLARITIN and CLARINEX (desloratadine), a non-sedating antihistamine, were $143 million, up 9 percent, and sales of NASONEX were $37 million, up 35 percent. In anti-infective/anticancer, sales of the INTRON A franchise totaled $169 million, up 16 percent versus the comparable 2000 period, benefiting from the March 2001 European Union approval of PEG-INTRON and REBETOL combination therapy for the treatment of chronic hepatitis C. Also contributing to second quarter international sales were TEMODAR, with sales of $18 million, up 34 percent, and REMICADE.

Second quarter sales of animal health products were down 1 percent (up 3 percent when foreign exchange is excluded). Sales of Schering-Plough's foot care products decreased 3 percent and over-the-counter (OTC) products were down 5 percent versus the comparable 2000 period. Sales of sun care products were up 28 percent versus the 2000 period.

2001 FIRST HALF RESULTS

Worldwide pharmaceutical sales in the 2001 first half decreased 2 percent (up 1 percent when foreign exchange is excluded) to $4.2 billion.

Sales of domestic pharmaceuticals totaled $2.6 billion, down 6 percent versus the 2000 first half, with sales affected by manufacturing issues and changes in the timing of trade buying, tempered by increased demand for certain products. The sales decline was due to lower sales of VANCENASE and the VANCERIL (beclomethasone dipropionate) line of orally inhaled steroids for asthma; lower sales of K-DUR, and lower sales of the INTRON A franchise. Also contributing to lower sales in the 2001 first half were LOTRISONE (clotrimazole and betamethasone dipropionate), a topical antifungal/anti-inflammatory, and IMDUR, which declined due to continued generic competition. The overall sales decline for U.S. pharmaceuticals was moderated by higher sales of CLARITIN, NASONEX, TEMODAR and INTEGRILIN.

International pharmaceutical sales for the period rose 5 percent (up 12 percent when foreign exchange is excluded) and totaled $1.6 billion. Higher sales were led by NASONEX, the INTRON A franchise, REMICADE and TEMODAR.

Sales of animal health products decreased 2 percent in the 2001 first half (up 2 percent when foreign exchange is excluded) and totaled $324 million. Sales of Schering-Plough's foot care products decreased 7 percent versus the prior year. Sales of OTC products were up 12 percent compared with the prior period. Schering-Plough's sun care products were up 10 percent in the 2001 first half versus the prior year.

DISCLOSURE NOTICE: In addition to historical information, this press release includes certain "forward-looking" statements relating to the company's business prospects and the expected impact on the company of the manufacturing process and control and current Good Manufacturing Practices (GMP) issues identified by the FDA, the company's efforts going forward to resolve those issues, remedies the FDA may seek with respect to those issues, the expected need for and cost of any additional remedial actions the company may take and the pendency of the company's New Drug Applications (NDA) for CLARINEX, which remain subject to FDA approval. The reader of this release should understand that the resolution of the issues with the FDA, as well as the potential impact of those issues on the company's full-year 2001 sales and earnings, are subject to substantial risks and uncertainties, and those issues could cause actual results to differ materially from the company's forward-looking statements. Many factors could cause actual results to differ materially from the company's forward-looking statements, including that the timing, scope and duration of a resolution of the manufacturing process and control and GMP issues will depend on the ability of the company to assure FDA of the quality and reliability of its manufacturing systems and controls, and the extent of remedial and prospective obligations undertaken by the company. Other risk factors include that the FDA approval process is uncertain and can cause delays in the release of products, seizure or recall of products, suspension or revocation of the authority necessary for the production and sale of products, fines and other civil or criminal sanctions. In addition to the risks and uncertainties relating to the company's manufacturing deficiencies, the forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, current and future branded and generic competition for the company's products, federal and state regulations and legislation, the regulatory process for new products and indications, new manufacturing issues that may arise, timing of trade buying, exchange rate fluctuations, patent positions, litigation and investigations. For further details and a discussion of these and other risks and uncertainties, see the company's Securities and Exchange Commission filings, including the company's 2000 annual report on Form 10-K and subsequent quarterly report on Form 10-Q.

Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.

SCHERING-PLOUGH CORPORATION
Report for the second quarter ended June 30 (unaudited):
(Amounts in millions, except per share figures)

			Second Quarter				% Change
			2001		2000
Net Sales			$	2,630	$	2,626	--
Costs and Expenses:
	Cost of Sales		535		489		9
	Selling, General
		and Administrative	967		977		(1)
	Research and Development		334		345		(3)
	Other, Net		(29)		(19)		53
			1,807		1,792		1
Income Before Income Taxes			823		834		(1)
Income Taxes			189		200		(5)
Net Income			$	634	$	634	--
Diluted Earnings Per Common Share			$	0.43	$	0.43	--
Effective Tax Rate			23.0%		24.0%
Average Number of Common Shares Outstanding- Diluted			1,470		1,476
Actual Number of Common Shares Outstanding at June 30				1,463		1,465

Excluding exchange, diluted earnings per share for the second quarter increased 2 percent.

SCHERING-PLOUGH CORPORATION
Report for the six months ended June 30 (unaudited):
(Amounts in millions, except per share figures)

			Six Months				% Change
			2001		2000
Net Sales			$	4,949	$	5,015	(1)
Costs and Expenses:
	Cost of Sales		1,005		946		6
	Selling, General
		and Administrative	1,819		1,818		--
	Research and Development		624		635		(2)
	Other, Net		(55)		(44)		27
			3,393		3,355		1
Income Before Income Taxes			1,556		1,660		(6)
Income Taxes			358		398		(10)
Net Income			$	1,198	$	1,262	(5)
Diluted Earnings Per Common Share			$	0.81	$	0.85	(5)
Effective Tax Rate			23.0%		24.0%
Average Number of Common Shares Outstanding- Diluted			1,471		1,478
Actual Number of Common Shares Outstanding at June 30			1,463		1,465

Excluding exchange, diluted earnings per share for the first half of 2001 decreased 1 percent.

Net Sales by Major Product:
(Dollars in millions)

		Second Quarter
		2001		2000		%
ALLERGY & RESPIRATORY		$	1,244	$	1,216	2
Claritin			925		897	3
Nasonex			183		121	51
Vancenase			(2)		54	N/M
Proventil			66		55	21
Vanceril			22		27	(17)
ANTI-INFECTIVE & ANTICANCER		510		508		--
Eulexin		19		26		(25)
Intron A franchise*		315		361		(13)
Remicade		36		12		N/M
Temodar		44		30		46
CARDIOVASCULARS		134		168		(20)
Imdur		18		33		(46)
Integrilin		67		42		60
K-Dur		19		54		(64)
Nitro-Dur		29		32		(8)
DERMATOLOGICALS		176		170		4
Elocon		51		44		15
Lotrisone		48		48		1
OTHER PHARMACEUTICALS		164		174		(6)
	WORLDWIDE PHARMACEUTICALS	2,228		2,236		--
ANIMAL HEALTH		171		173		(1)
FOOT CARE		97		100		(3)
OTC		42		45		(5)
SUN CARE		92		72		28
CONSOLIDATED NET SALES		$	2,630	$	2,626	--

N/M - not a meaningful percentage.

* The Intron A franchise includes INTRON A, PEG-INTRON (monotherapy for treating hepatitis C and, internationally, in combination with REBETOL), and REBETRON Combination Therapy.

NOTE: Additional information about U.S. and international sales for specific products is available by calling the company or visiting the corporate Web site at www.schering-plough.com.

Net Sales by Major Product:
(Dollars in millions)

		Six Months
		2001		2000		%
ALLERGY & RESPIRATORY		$	2,171	$	2,172	--
Claritin			1,643		1,562	5
Nasonex			274		202	36
Vancenase			1		110	(99)
Proventil			106		99	7
Vanceril			34		64	(47)
ANTI-INFECTIVE & ANTICANCER		1,035		1,000		3
Eulexin		49		63		(23)
Intron A franchise*		641		697		(8)
Remicade		63		20		N/M
Temodar		87		51		69
CARDIOVASCULARS		297		351		(15)
Imdur		39		68		(43)
Integrilin		105		70		51
K-Dur		94		132		(29)
Nitro-Dur		55		67		(17)
DERMATOLOGICALS		318		342		(7)
Elocon		103		88		17
Lotrisone		60		98		(38)
OTHER PHARMACEUTICALS		355		383		(7)
	WORLDWIDE PHARMACEUTICALS	4,176		4,248		(2)
ANIMAL HEALTH		324		330		(2)
FOOT CARE		176		190		(7)
OTC		98		87		12
SUN CARE		175		160		10
CONSOLIDATED NET SALES		$	4,949	$	5,015	(1)

N/M - not a meaningful percentage.

* The Intron A franchise includes INTRON A, PEG-INTRON (monotherapy for treating hepatitis C and, internationally, in combination with REBETOL), and REBETRON Combination Therapy.

Note: Additional information about U.S. and international sales for specific products is available by calling the company or visiting the corporate Web site at www.schering-plough.com.